Use of angiotensin system inhibitors is associated with immune activation and longer survival in nonmetastatic pancreatic ductal adenocarcinoma

Clinical Cancer Research

Volumn 23, Issue 19, 2017, Pages 5959-5969

  Liu, Hao ^a,b   Naxerova, Kamila ^a,e   Pinter, Matthias ^a   Incio, Joao ^a,f   Lee, Hang ^a   Shigeta, Kohei ^a   Ho, William W ^a,c   Crain, Jonathan A ^a,g   Jacobson, Alex ^a,h   Michelakos, Theodoros ^a   Dias Santos, Daniella ^a,i   Zanconato, Andrea ^a   Hong, Theodore S ^a   Clark, Jeffrey W ^a   Murphy, Janet E ^a   Ryan, David P ^a   Deshpande, Vikram ^a   Lillemoe, Keith D ^a   Castillo, Carlos Fernandez del ^a   Downes, Michael ^d   Evans, Ronald M ^d   Michaelson, James ^a   Ferrone, Cristina R ^a   Boucher, Yves ^a   Jain, Rakesh K ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF PORTO   (Portugal)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h UNIVERSITY OF VERMONT   (United States)

ⁱ NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LISINOPRIL; OXALIPLATIN; ANGIOTENSIN DERIVATIVE; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ADVANCED CANCER; AGED; ANTIGEN PRESENTING CELL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOSTIMULATION; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NOTCH SIGNALING; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RNA SEQUENCE; T LYMPHOCYTE; TREATMENT DURATION; TUMOR MICROENVIRONMENT; UNITED STATES; VALIDATION PROCESS; WNT SIGNALING; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; PANCREAS CARCINOMA; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; ANGIOTENSINS; ANTIGEN-PRESENTING CELLS; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS;

EID: 85030537609     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-0256     Document Type: Article

References (50)

1. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2010;2:247–57.
2. George AJ, Thomas WG, Hannan RD. The renin–angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 2010;10:745–59.
3. Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A 2009;106:10284–9.
4. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60:2497–503.
5. Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A 2011;108:2909–14.
6. Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun 2013; 4:2516.
7. Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N, et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A 2012; 109:15101–8.
8. Nia HT, Liu H, Seano G, Datta M, Jones D, Rahbari N, et al. Solid stress and elastic energy as measures of tumour mechanopathology. Nat Biomed Eng 2016;1:0004.
9. Murphy JE, Wo JY, Ferrone CR, Wenqing J, Yeap B, Blaszkowsky LS, et al. TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): preliminary feasibility and R0 resection rates from a prospective phase II study. 2017 Gastrointestinal Cancers Symposium, Virtual Meeting, Meeting Library [Internet]. J Clin Oncol 35, 2017(suppl 4S; abstract 386).
10. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 2012;7:562–78.
11. Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SGH, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 2015;47:1168–78.
12. Drier Y, Sheffer M, Domany E. Pathway-based personalized analysis of cancer. Proc Natl Acad Sci U S A 2013;110:6388–93.
13. Busby MA, Stewart C, Miller CA, Grzeda KR, Marth GT. Scotty: a web tool for designing RNA-Seq experiments to measure differential gene expression. Bioinformatics 2013;29:656–7.
14. Kuma A, Yamada S, Wang KY, Kitamura N, Yamaguchi T, Iwai Y, et al. Role of WNT10A-expressing kidney fibroblasts in acute interstitial nephritis. PLoS One 2014;9:e103240.
15. Mukaida N, Sasaki SI, Baba T. Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment. Mediators Inflamm 2014;2014:170381.
16. Marsland BJ, B€attig P, Bauer M, Ruedl C, L€assing U, Beerli RR, et al. CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity 2005;22:493–505.
17. Murphy TL, Grajales-Reyes GE, Wu X, Tussiwand R, Briseño CG, Iwata A, et al. Transcriptional control of dendritic cell development. Annu Rev Immunol 2016;34:93–119.
18. Sabbagh L, Snell LM, Watts TH. TNF family ligands define niches for T cell memory. Trends Immunol 2007;28:333–9.
19. Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 2010;103:1644–8.
20. Nakai Y, Isayama H, Ijichi H, Sasaki T, Kogure H, Yagioka H, et al. Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Cancer Sci 2012;103:1489–92.
21. Nakai Y, Isayama H, Ijichi H, Sasaki T, Takahara N, Ito Y, et al. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Invest New Drugs 2013;31:1294–9.
22. Horowitz DP, Hsu CC, Wang J, Makary MA, Winter JM, Robinson R, et al. Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2011;80:1391–7.
23. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer. JAMA 2013;310:1473.
24. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013;31:2205–18.
25. Watt J, Kocher HM. The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration. Oncoimmunology 2013;2: e26788.
26. Whatcott CJ, Han H, Hoff Von DD. Orchestrating the tumor microenvironment to improve survival for patients with pancreatic cancer: normalization, not destruction. Cancer J 2015;21:299–306.
27. Jain RK, Martin JD, Stylianopoulos T. The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng 2014;16:321–46.
28. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014;26:605–22.
29. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012;109:17561–6.
30. Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, Yeo CJ. Antihyperten-sives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 2007;204:996–1005.
31. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 2001;495: 197–200.
32. Avila JL, Kissil JL. Notch signaling in pancreatic cancer: oncogene or tumor suppressor? Trends Mol Med 2013;19:320–7.
33. Zhang Y, Morris JP, Yan W, Schofield HK, Gurney A, Simeone DM, et al. Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Res 2013;73:4909–22.
34. Sano M, Driscoll DR, DeJesus-Monge WE, Quattrochi B, Appleman VA, Ou J, et al. Activation of WNT/b-catenin signaling enhances pancreatic cancer development and the malignant potential via up-regulation of Cyr61. Neoplasia 2016;18:785–94.
35. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007;67:9518–27.
36. Clark CE, Beatty GL, Vonderheide RH. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett 2009;279:1–7.
37. Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov 2016;6:270–85.
38. Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 2013;108:914–23.
39. Cortez-Retamozo V, Etzrodt M, Newton A, Ryan R, Pucci F, Sio SW, et al. Angiotensin II drives the production of tumor-promoting macrophages. Immunity 2013;38:296–308.
40. Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, et al. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. Cancer Discov 2016;6:852–69.
41. Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer 2016;16:447–62.
42. Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti SC, et al. TGFb is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res 2015;75:2232–42.
43. Yuan C, Rubinson DA, Qian ZR, Wu C, Kraft P, Bao Y, et al. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol 2015;33:29–35.
44. Incio J, Suboj P, Chin SM, Vardam-Kaur T, Liu H, Hato T, et al. Metformin reduces desmoplasia in pancreatic cancer by reprogramming stellate cells and tumor-associated macrophages. PLoS One 2015;10:e0141392.
45. Amin S, Mhango G, Lin J, Aronson A, Wisnivesky J, Boffetta P, et al. Metformin improves survival in patients with pancreatic ductal adenocarcinoma and pre-existing diabetes: a propensity score analysis. Am J Gastro-enterol 2016;111:1350–7.
46. Ambe CM, Mahipal A, Fulp J, Chen L, Malafa MP. Effect of metformin use on survival in resectable pancreatic cancer: a single-institution experience and review of the literature. PLoS One 2016;11:e0151632.
47. Kordes S, Pollak MN, Zwinderman AH, Mathôt RA, Weterman MJ, Beeker A, et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2015; 16:839–47.
48. Incio J, Tam J, Rahbari NN, Suboj P, McManus DT, Chin SM, et al. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity. Clin Cancer Res 2016; 22:2993–3004.
49. Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K, et al. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol 2013;31: 4229–34.
50. Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 2015;261:12–7.